] i oscillations essentially rely only on the specific properties of the InsP 3 receptors on the intracellular Ca 2ϩ stores, the oscillations are also associated with an enhanced entry of Ca 2ϩ across the plasma membrane. Importantly, the rate of this activated entry of Ca 2ϩ has been shown to have a profound influence on the frequency of the oscillations (5-8), apparently by affecting the ability of low levels of agonist-generated InsP 3 to induce the release of Ca 2ϩ from the stores (8, 9). The prevailing model of receptor-activated external Ca 2ϩ entry in nonexcitable cells is the so-called "capacitative" or store-operated model (10, 11) in which the emptying of the agonist-sensitive stores alone is both necessary and sufficient to activate Ca 2ϩ entry. However, we have recently described a novel mechanism of agonist-activated Ca 2ϩ entry that is independent of store depletion (i.e. noncapacitative) and that is entirely dependent on the receptor-mediated generation of arachidonic acid (12, 13). The evidence suggests that the Ca 2ϩ entry pathway is activated by arachidonic acid itself, not a metabolite, and is entirely distinct from the capacitative or store-operated pathway (12) (13) (14) . Importantly, it is this novel entry pathway that appears to be the primary route for the receptor-induced entry of Ca 2ϩ that plays a critical role in the generation and modulation of the oscillatory [Ca 2ϩ ] i signals seen at low agonist concentrations.
The oscillatory [Ca 2؉ ] i signals typically seen following physiologically relevant stimulation of phospholipase C-linked receptors are associated with a receptor-activated entry of Ca 2؉ , which plays a critical role in driving the oscillations and influencing their frequency. We have recently shown that this receptor-activated entry of Ca 2؉ does not conform to the widely accepted "capacitative" model and, instead, reflects the activity of a distinct, novel Ca 2؉ entry pathway regulated by arachidonic acid (Shuttleworth, T. J., and Thompson, J. L. (1998) J. Biol. Chem. 273, 32636 -32643). We now show that the generation of arachidonic acid under these conditions results from the activity of a type IV cytosolic phospholipase A 2 (cPLA 2 ). Although cPLA 2 activation commonly involves a Ca 2؉ -dependent translocation to the membrane, at these low agonist concentrations cPLA 2 2؉ ] i , and no detectable translocation to the membrane occurs. Nevertheless, stimulation of cPLA 2 activity was confined to the membrane fraction, where an increase in phosphorylation of the enzyme was observed. We suggest that, at the low agonist concentrations associated with oscillatory [Ca 2؉ ] i signals, cPLA 2 activation involves an increased phosphorylation of a discrete pool of the total cellular cPLA 2 that is already localized within the membrane fraction at resting [Ca 2؉ ] i .
activation was independent of increases in [Ca
Many hormones and neurotransmitters exert their effects on their target cells through the receptor-mediated activation of phospholipase C and the subsequent generation of inositol 1,4,5-trisphosphate (InsP 3 ), 1 resulting in increases in [Ca 2ϩ ] i . In many nonexcitable cells, activation with physiological levels of agonist results in a [Ca 2ϩ ] i signal that takes the form of a series of repetitive [Ca 2ϩ ] i oscillations (1, 2) . In their simplest form, these oscillations consist of an InsP 3 -induced release of Ca 2ϩ from intracellular agonist-sensitive stores, followed by a subsequent reuptake of released Ca 2ϩ back into the stores via the sarcoplasmic-endoplasmic reticulum calcium pumps (3, 4) . Although such models for the agonist-activated [Ca 2ϩ ] i oscillations essentially rely only on the specific properties of the InsP 3 receptors on the intracellular Ca 2ϩ stores, the oscillations are also associated with an enhanced entry of Ca 2ϩ across the plasma membrane. Importantly, the rate of this activated entry of Ca 2ϩ has been shown to have a profound influence on the frequency of the oscillations (5) (6) (7) (8) , apparently by affecting the ability of low levels of agonist-generated InsP 3 to induce the release of Ca 2ϩ from the stores (8, 9 ). The prevailing model of receptor-activated external Ca 2ϩ entry in nonexcitable cells is the so-called "capacitative" or store-operated model (10, 11) in which the emptying of the agonist-sensitive stores alone is both necessary and sufficient to activate Ca 2ϩ entry. However, we have recently described a novel mechanism of agonist-activated Ca 2ϩ entry that is independent of store depletion (i.e. noncapacitative) and that is entirely dependent on the receptor-mediated generation of arachidonic acid (12, 13) . The evidence suggests that the Ca 2ϩ entry pathway is activated by arachidonic acid itself, not a metabolite, and is entirely distinct from the capacitative or store-operated pathway (12) (13) (14) . Importantly, it is this novel entry pathway that appears to be the primary route for the receptor-induced entry of Ca 2ϩ that plays a critical role in the generation and modulation of the oscillatory [Ca 2ϩ ] i signals seen at low agonist concentrations.
As yet, the mechanisms involved in the receptor activation of arachidonic acid generation under such conditions are unclear. Using HEK293 cells stably transfected with the human m3 muscarinic receptor (m3-HEK cells), we have previously shown that the generation of arachidonic acid following stimulation of the muscarinic receptor with low concentrations of agonist was independent of the simultaneous stimulation of phosphatidylinositol-specific PLC activity (13) . Further evidence suggested that this agonist-induced arachidonic acid generation probably involved a member of the PLA 2 enzyme family. However, the specific identity of the PLA 2 enzyme involved and the mechanism of its activation by low concentrations of muscarinic agonists remained unknown. We now show that the carbacholinduced generation of arachidonic acid seen in the m3-HEK cells reflects the activity of a type IV cPLA 2 . Increases in the activity of this enzyme induced by muscarinic receptor activation can be readily detected within the agonist concentration range known to result in arachidonic acid generation, as well as the activation of the noncapacitative entry of Ca 2ϩ that is associated with oscillatory [Ca 2ϩ ] i signals in these same cells. Although activation of the type IV cPLA 2 in cells commonly involves a Ca 2ϩ -dependent translocation of the enzyme to the membrane (15), we report that, at the low agonist concentrations used in this study, the activation of the cPLA 2 was independent of any change in [Ca 2ϩ ] i , and no significant transloca-tion to the membrane fraction could be detected. This [Ca 2ϩ ] iindependent activation of the type IV cPLA 2 seen at low concentrations of agonist may reflect the activation of a discrete pool of the total cellular cPLA 2 that is already localized within the membrane fraction at resting levels of [Ca 2ϩ ] i . Activation of this putative receptor-coupled pool of PLA 2 results in generation of arachidonic acid and an increase in Ca 2ϩ entry.
EXPERIMENTAL PROCEDURES
Materials-The HEK293 cell line stably transfected with the human m3 muscarinic receptor (m3-HEK cells) was obtained from Dr. Craig Logsdon (University of Michigan, Ann Arbor, MI). Silica G plates were obtained from Alltech Associates Inc. AACOCF 3 , HELSS, arachidonic acid, and isotetrandrine were obtained from Biomol. Methanol, acetic acid, and hexane were all from EM Science. Leupeptin, soybean trypsin inhibitor, aprotinin, and phenylmethylsulfonyl fluoride were from Sigma; pepstatin A was from Roche Molecular Biochemicals; and okadaic acid was from Calbiochem.
3 H-Labeled L-1-sterol-2-arachidonyl phosphatidylcholine was from NEN Life Science Products (NET872). Monoclonal antibodies directed against the amino terminus of human type IV cPLA 2 were from Santa Cruz Biotechnology, Inc. (SC-454), and secondary antibody (rabbit anti-mouse IgG conjugated to horseradish peroxidase) was from Sigma (A-2304).
In Vitro PLA 2 Activity Assay-This assay uses phosphatidylcholine, which is a common substrate of most PLA 2 enzymes. The phosphatidylcholine used has a [ 3 H]arachidonyl moiety at the sn-2-position, and the release of free arachidonic acid is a measure of PLA 2 enzyme activity. Cells were cultured in 10-cm Petri dishes until subconfluent. Prior to the experiment, the cells were preincubated in saline of the following composition: 132 mM sodium chloride, 4.8 mM potassium chloride, 1.2 mM magnesium sulfate, 1.3 mM calcium chloride, 1.2 mM potassium dihydrogen-phosphate, 6 mM glucose, 5.95 mM HEPES free acid, 9.05 mM HEPES sodium salt, pH 7.4. Agonists and/or drugs were added to this saline as appropriate and for the times indicated. Following preincubation, cells were placed on ice and washed twice with ice-cold saline. Cells were removed from the plate in ice-cold saline with the addition of 1.25 mM EDTA and centrifuged at 60 ϫ g. The cell pellet was resuspended in homogenization buffer (40 mM Tris, pH 7.8, 1 mg/ml bovine serum albumin) and sonicated on ice. Following centrifugation at 10,000 ϫ g for 5 min, the supernatants were transferred to tubes on ice. To determine PLA 2 activity, samples of the total cell lysate (100 l) were mixed with an equal volume of a solution containing 2.5 nCi of [ 3 H]phosphatidylcholine dissolved in 50 l of Me 2 SO plus 950 l of assay buffer (40 mM Tris, pH 7.8, 10% Me 2 SO, 1 mM Ca 2ϩ ) and incubated for 30 min at 37°C. Reactions were stopped by the addition of methanol/chloroform/acetic acid (4:2:0.5), and lipids were extracted and resolved on a Silica-G TLC plate using a modified version of the Bligh and Dyer method (16) . Bands corresponding to arachidonic acid were visualized by iodine staining of a standard sample and scraped. Activity was determined by scintillation counting of the scraped silica samples and normalized to total protein in the sample, determined by Coomassie reagent (Pierce). Typical counts for the cell lysate samples were in the range of 1000 -4000 cpm/sample. Where indicated, total cell lysates obtained as described above were separated into cytosolic and membrane fractions by centrifugation at 100,000 ϫ g for 40 min at 4°C. The resulting supernatant was termed the cytosol fraction, while the pellet was termed the membrane fraction.
Immunoblotting-Cell pellets, obtained after centrifugation at 60 ϫ g as described above, were resuspended in saline containing protease inhibitors (2 g/ml leupeptin, 10 g/ml soybean trypsin inhibitor, 1 g/ml aprotinin, 1 g/ml pepstatin A, 133 M phenylmethylsulfonyl fluoride) and okadaic acid (20 M) and sonicated on ice, followed by centrifugation at 10,000 ϫ g for 3 min at 4°C. The resulting supernatant was centrifuged at 100,000 ϫ g for 40 min at 4°C. to obtain a pellet (membrane fraction) that was resuspended in running buffer. 100 -200 g of total protein per lane was separated by electrophoresis on a 6 or 8% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane, and blocked overnight in Tris-buffered saline (pH 7.5) plus 1% nonfat dry milk and 0.05% Tween 20. The nitrocellulose membrane was incubated in the anti-cPLA 2 primary antibody (diluted 1:500) for 90 min at room temperature, washed three times with Tris-buffered saline, and then incubated in the secondary antibody (1:5000), followed by a second set of three washes with Tris-buffered saline. Bands were visualized with Super Signal ® Chemiluminescent substrates (Pierce). Densitometric analysis was performed on the resolved bands using the AlphaImager 2000 documentation and analysis system and AlphaEase software (Alpha Innotech). Preliminary experiments showed that, with the protein loading used, resolved bands were within the linear range of analysis.
RESULTS
The liberation of arachidonic acid from phosphatidylcholine can occur via a variety of different pathways. It was therefore important to confirm that the assay we have employed was genuinely reporting the activity of a PLA 2 enzyme. The most likely alternative was a phospholipase D activity that can hydrolyze phosphatidylcholine to phosphatidic acid and choline. The phosphatidic acid can then be acted upon by phosphatidic acid phosphohydrolase to yield diacylglycerol from which arachidonic acid can be released via the action of diacylglycerol and monoacylglycerol lipases. It is possible that the whole cell lysates used could contain such activities and could have resulted in the release of [ 3 H]arachidonic acid in the assay. To examine this possibility, the cell lysates were incubated in the presence of ethanol or butanol. These agents have been shown to replace water as a donor in the hydrolysis of phosphatidylcholine to choline and diacylglycerol, thereby leading to a loss of arachidonic acid generation. However, treatment of the lysates with 2% ethanol or 100 mM butanol failed to significantly inhibit either resting enzyme activity or the carbachol-stimulated activity measured in the assay (Fig. 1 ). Neither component, therefore, involves the action of a phospholipase D.
To determine whether the PLA 2 activity we were recording in the enzyme assay could realistically account for the arachidonic acid generation we have previously observed in intact cells, the sensitivity of the measured PLA 2 activity in the m3-HEK cells to stimulation with low concentrations of carbachol (0.5-3.0 M) was examined. The data obtained show that significant stimulation of PLA 2 activity could be readily detected at carbachol concentrations as low as 0.5 M, and the activity was further increased at 1 and 3 M, where an approximate 3-fold stimulation was observed (Fig. 2) . This is precisely the concentration range over which we see carbachol-induced increases in arachidonic acid generation and the subsequent m3-type muscarinic acetylcholine receptor-induced activation of the noncapacitative, arachidonic acid-dependent entry of Ca 2ϩ (13) . Moreover, although the above assays were performed after a 5-min stimulation with carbachol, additional experiments showed that significant increases in activity of the PLA 2 could be readily detected within 1 min of the addition of carbachol (1.75 Ϯ 0.12-fold stimulation (n ϭ 3) with 1 M carbachol). Again this is consistent with the enzyme activity determined here being responsible for the previously reported arachidonic acid generation in intact cells.
Identification of the PLA 2 Subtype Involved-PLA 2 activity is demonstrated by a family of distinct enzymes with markedly different molecular structures, pharmacological profiles, and enzymatic mechanisms. The reducing agent dithiothreitol has been shown to inhibit the secretory PLA 2 enzymes (types I, II, III, and V) by virtue of disrupting intramolecular disulfide bonds. To examine the possibility that the measured activity involves a member of the secretory PLA 2 family, preliminary assays performed in the presence and absence of 1 mM dithiothreitol were compared. Under control (unstimulated) conditions, measured PLA 2 activity in the presence of dithiothreitol was 103% of that seen in the absence of dithiothreitol (mean of duplicate experiments). In cells stimulated with 1 M carbachol, this activity increased to 2.8-fold in the absence of dithiothreitol and 3.15-fold in the presence of dithiothreitol (mean of duplicate experimemts). These data demonstrate that neither the basal PLA 2 activity nor the carbachol-stimulated activity is inhibited by dithiothreitol and, therefore, excludes the involvement of a member of the secretory PLA 2 family. As an added precaution, all subsequent assays were performed in the presence of 1 mM dithiothreitol.
In contrast, the compound AACOCF 3 (10 M) markedly inhibited both the basal and carbachol-stimulated PLA 2 activity determined in whole cell lysates (Fig. 3) . AACOCF 3 , an active site-directed inhibitor, was originally thought to be specific for the type IV cPLA 2 , but subsequent studies have shown that it is also an effective inhibitor of the type VI PLA 2 (iPLA 2 ) (17). It is without affect on the secretory PLA 2 enzymes. The data obtained therefore indicate that either a cPLA 2 or iPLA 2 is responsible for the activity measured. To distinguish between these two possibilities, we used the haloenol lactone suicide substrate HELSS, which has been shown to be a potent and specific inhibitor of the type VI iPLA 2 , with a greater than 1000-fold selectivity for iPLA 2 over cPLA 2 (18 -20) . Experiments showed that both basal and carbachol-stimulated PLA 2 activity in the m3-HEK cell lysates were unaffected by HELSS (Fig. 3) . Based on the combined evidence from the experiments using AACOCF 3 and HELSS, it is concluded that the PLA 2 activity observed, including the portion that is sensitive to stimulation by the muscarinic agonist carbachol, reflects the action of a type IV PLA 2 . Immunoblotting of SDS-polyacrylamide gels using a specific antibody to the human type IV cPLA 2 subtype confirmed that the m3-HEK cells do indeed express a type IV cPLA 2 enzyme ( Fig. 6; see below) .
Muscarinic Receptor Activation of the Type IV PLA 2 -In previous studies, we have shown that the carbachol-stimulated release of arachidonic acid in intact cells is entirely independent of the simultaneous activation of PLC or of either of the two main consequences of PLC activation, namely an increase in [Ca 2ϩ ] i and the activation of PKC (13) . Nevertheless, it is generally considered that a key step in the receptor activation of the type IV PLA 2 in most cells is a Ca 2ϩ -dependent translocation of the enzyme to its substrate in the membrane involving Ca 2ϩ -independent Activation of cPLA 2 a Ca 2ϩ -dependent phospholipid-binding domain present in the amino terminus of the type IV PLA 2 protein (21-23). We therefore examined the [Ca 2ϩ ] i dependence of the agonist-induced stimulation of cPLA 2 activity in the m3-HEK cell lysates. Consistent with our earlier studies on arachidonic acid release in intact cells (13) , preloading the cells with the Ca 2ϩ chelator BAPTA sufficient to completely block any agonist-induced [Ca 2ϩ ] i signal failed to affect the carbachol-induced stimulation of cPLA 2 activity (Fig. 4) . Nevertheless, additional experiments where the cell lysates were separated into membrane and cytosol fractions revealed that the agonist-induced stimulation of activity did occur exclusively within the membrane fraction (Fig. 5) . Importantly, these data cannot result from any limitations on availability of substrate in the cytosolic fraction, since excess exogenous substrate is provided in the enzyme assay. Although this observed increase in the membrane-associated enzyme activity could reflect the transfer of enzyme from the cytosol to the membrane pool, our observation that the overall stimulation of cPLA 2 activity was independent of any increase in [Ca 2ϩ ] i suggests that the normal Ca 2ϩ -dependent translocation of cPLA 2 to the membrane does not play any significant role in the muscarinic receptor activation of the enzyme, at least at the low agonist concentrations used in this study. Alternatively, the increase in membrane-associated activity could result from an agonist-induced stimulation of a component of the total cPLA 2 enzyme that is already localized within the membrane fraction. To examine this possibility, membrane fractions were subjected to SDS-polyacrylamide gel electrophoresis, and the resulting gels were probed using immunoblotting with a specific antibody against the type IV cPLA 2 . Immunoreactive bands of the appropriate molecular size (approximately 100 kDa) (24) were readily detected, but the data obtained revealed marked differences in the fractions from control versus carbachol-stimulated cells (Fig. 6 ). Most obvious was that the position of the cPLA 2 immunoreactivity appeared to shift to a more slowly migrating electrophoretic form in the fractions from stimulated cells. Such a gel shift is known to correlate with an increased phosphorylation of cPLA 2 (24) , and this was confirmed by treatment of the fractions with alkaline phosphatase, which resulted in the reversal of the observed gel shift in the fractions from stimulated cells (data not shown). Furthermore, the carbachol-induced gel shift was not observed in fractions from cells treated with atropine (10 M). Based on this, we conclude that that stimulation of the m3 muscarinic receptors on the cells with 1 M carbachol results in a significant increase in the phosphorylation state of the membrane-associated enzyme. Importantly, when the same densitometric analysis was used to measure the total immunoreactivity (i.e. sum of the density measured over an area covering the location of both bands), no significant difference was detected in the fractions from control and stimulated cells despite identical levels of protein being applied to the gel in the two lanes. Thus the total density of the immunoreactive bands in the membrane fractions from carbachol-stimulated cells was 8251 90.3 Ϯ 4.8% of that in control cells (mean Ϯ S.E., n ϭ 3). The clear implication is that no significant translocation of enzyme to the membrane-associated fraction occurred upon stimulation, despite the observed approximately 2-fold increase in enzyme activity in the membrane fractions. Interestingly, examination of the in vitro Ca 2ϩ dependence of the cPLA 2 activity measured in the assay revealed marked differences between the cytosolic and membrane-associated enzyme pools. Similar to previous reports (see, for example, Ref. 25) , increasing the Ca 2ϩ concentration in the enzyme assay over the range of nominally Ca 2ϩ -free to 5 mM resulted in marked increases in measured activity. However, whereas the activity in the cytosolic fraction increased more than 20-fold over this range of Ca 2ϩ concentrations, that in the membrane fraction showed only a 2-fold increase (-fold increase equals 23.1 Ϯ 7.1 in the cytosol fraction compared with 2.1 Ϯ 0.6 in the membrane fraction, n ϭ 3). This demonstrates that the membrane-associated pool of enzyme has a markedly different in vitro Ca 2ϩ sensitivity compared with the cytosolic enzyme.
DISCUSSION
In this study, we have examined the nature of the release of arachidonic acid seen in m3-HEK cells following stimulation with the muscarinic agonist carbachol at concentrations known to result in the activation of the noncapacitative arachidonic acid-dependent entry of Ca 2ϩ and the generation of oscillatory [Ca 2ϩ ] i signals. The generation of free arachidonic acid following receptor stimulation can result from the activity of a variety of different phospholipases including PLA 2 , PLC, and phospholipase D (26) . We have previously argued that the receptoractivated arachidonic acid generation we have observed in these cells is unlikely to involve the activity of a phospholipase D and that it appeared to be independent of the simultaneous activation of PLC (13) . The remaining phospholipase, PLA 2 , has many subtypes that show a wide diversity in function, structure, and regulation (27) (28) (29) . The type I-III and type V PLA 2 enzymes are secretory, do not show specificity for the fatty acid moiety at the sn-2-position of phosphatidylcholine, and require millimolar concentrations of Ca 2ϩ for activity. The type IV and VI PLA 2 enzymes are cytosolic and show a preference for the hydrolysis of phosphatidylcholine possessing an arachidonyl moiety at the sn-2-position, thereby leading to the release of arachidonic acid. The type IV PLA 2 typically requires submicromolar concentrations of Ca 2ϩ for translocation to its substrate in the membranes (15, 22) , while the type VI PLA 2 has no calcium requirement for activity. Both the type IV PLA 2 (cPLA 2 ), and type VI PLA 2 (iPLA 2 ) have been shown to be activated following agonist binding to receptors and to result in the release of arachidonic acid. However, the type VI PLA 2 is considered to be principally involved in the restructuring of membranes by reincorporating free arachidonic acid into phospholipid (Refs. 17 and 30; but see Ref. 31 ). In contrast, it is the type IV cPLA 2 that is generally thought to be the principal enzyme involved in agonist-induced arachidonic acid generation. Consistent with this, agonist binding to various cell surface receptors, including muscarinic receptors, has been shown to lead to the activation of cPLA 2 and the generation of arachidonic acid in several different cell types (12, 13, 32, 33) . In this study, we have demonstrated that the arachidonic acid generation we have previously observed in the m3-HEK cells following activation of muscarinic receptor at low concentrations of agonists results from the activity of a type IV cPLA 2 . Stimulation of this enzyme occurred over the same agonist concentration range as the previously observed generation of arachidonic acid and could be readily detected within 1 min of agonist addition.
In general, receptor-mediated activation of type IV cPLA 2 is a complex process involving both increases in [Ca 2ϩ ] i and phosphorylation of the enzyme (23, 29). As noted above, the dependence on increases in [Ca 2ϩ ] i reflects a Ca 2ϩ -dependent translocation of the enzyme to the membrane, where it is exposed to its substrate. Stimulation of the enzyme activity per se is thought to be via a phosphorylation event that usually involves a serine at position 505 in the molecule and can result in 2-4-fold stimulation of activity (24, 34) . In most cases, this phosphorylation has been shown to result from an activation of the mitogen-activated protein kinase cascade and/or protein kinase C. Phosphorylation of cPLA 2 by both of these pathways has been well documented (23, 29) . Furthermore, both the mitogen-activated protein kinase cascade and protein kinase C activity have been shown to be stimulated following activation of muscarinic (and other) receptors (35, 36) .
The commonly observed requirement for an increase in [Ca 2ϩ ] i and a protein kinase C-dependent phosphorylation has lead to the current consensus that receptor-mediated stimulation of the type IV cPLA 2 is most often a downstream consequence of the activation of a phosphatidylinositol-specific PLC (37) . However, our previous findings on arachidonic acid release (13), together with those reported here for the activation of cPLA 2 , clearly demonstrate that, at the low concentrations of agonist used in these studies, the carbachol-induced generation of arachidonic acid involves the activation of a cPLA 2 via a mechanism that is independent of the simultaneous stimulation of PLC activity, including any increases in [Ca 2ϩ ] i . As discussed, such a finding is contrary to the general view that agonist-induced increases in [Ca 2ϩ ] i play a critical role in the receptor activation of cPLA 2 by inducing the translocation of the enzyme to the membrane (37) . A [Ca 2ϩ ] i -independent translocation of cPLA 2 has been described by Bayon et al. (32) in 1321N1 human astrocytoma cells in response to activation of muscarinic receptors and in vascular endothelial cells by Buckley et al. (38) . Recently, Qiu et al. (39) reported that the activation of cPLA 2 in macrophages by PMA and by okadaic acid also occurs without any measurable increase in [Ca 2ϩ ] i . Further studies using Sf9 cells expressing the human cPLA 2 dem- FIG. 6 . Immunoblots of the type IV cPLA 2 from the membrane fractions of control and carbachol-treated cells in the presence and absence of atropine. Membrane fractions from control cells and from cells exposed to 1 M carbachol, both in the absence and presence of atropine (10 M), were subjected to SDS-polyacrylamide gel electrophoresis, and the gel was probed using a specific antibody against the type IV cPLA 2 (see "Experimental Procedures" for details). The arrows indicate the position of the unphosphorylated form of the enzyme (cPLA 2 ) and the more slowly migrating phosphorylated form (cPLA 2 -P).
Ca 2ϩ -independent Activation of cPLA 2 8252 onstrated that, although independent of any increases in [Ca 2ϩ ] i , this activation nevertheless does involve a translocation step that is dependent on the activity of the amino-terminal Ca 2ϩ -dependent phospholipid-binding domain and requires resting levels of [Ca 2ϩ ] i (40) . Of course, in these studies as well as our own, it is difficult to definitively exclude a translocation that relies on undetectably small or highly localized changes in [Ca 2ϩ ] i . However, this possibility is certainly minimized in our experiments by the use of BAPTA, whose rapid binding characteristics would severely limit such localized changes in [Ca 2ϩ ] i . Furthermore, in all of the above reports, immunoblot analyses clearly revealed a definite translocation of enzyme to the membrane fraction, while no such translocation could be detected by similar techniques in our studies. Given the magnitude of the increase in membrane-associated cPLA 2 activity we have observed (approximately 2-fold), if this increase were solely (or even principally) due to a translocation of enzyme to the membrane then we should certainly have been able to detect it.
If we accept the possibility that no translocation step is involved in the activation of the cPLA 2 we have observed, then an alternative explanation is that, at the low agonist concentrations used in this study, receptor-mediated activation may occur within a pool of PLA 2 that is already located within the membrane fraction. A novel membrane-associated cPLA 2 (cPLA 2 -␥) has been recently described (41, 42) . Moreover, this enzyme lacks the Ca 2ϩ -dependent phospholipid-binding domain, and its activation is therefore entirely Ca 2ϩ -independent. However, at an estimated molecular size of around 60 kDa, this enzyme is significantly smaller than the "classical" type IV cPLA 2 (cPLA 2 -␣) and lacks the sequence to which the antibody used in our experiments was directed. Given this, any role for the cPLA 2 -␥ subtype in the responses observed here would not explain the pronounced effects on the phosphorylation state of the cPLA 2 seen in our immunoblot experiments.
Alternatively, cPLA 2 has been shown to possess a high binding affinity for certain anionic phospholipids, and such binding can result in dramatic effects on the enzyme activity. Leslie and Channon (25) first showed that anionic phospholipids were potent stimulators of the macrophage cPLA 2 , with phosphatidylinositol 4,5-bisphosphate being particularly effective. Subsequent studies by Mosior et al. (43) demonstrated a specific effect of low concentrations of phosphatidylinositol 4,5-bisphosphate that involved both marked increases in the affinity of cPLA 2 for binding to lipid and even greater increases in actual enzyme activity. Significantly, Leslie and Channon (25) showed that low concentrations of phosphatidylinositol 4,5-bisphosphate also dramatically decreased the Ca 2ϩ concentration required for maximum activity from the millimolar range to the nanomolar range. The evidence shows that this combination of actions is capable of producing dramatic increases in enzyme activity even at Ca 2ϩ levels typical of resting cells (70 nM) (43) . In this context, our finding that the cytosolic enzyme demonstrated a much larger stimulation in activity upon increasing the assay Ca 2ϩ concentration compared with the membraneassociated enzyme may be relevant. Such an effect is certainly consistent with the above reports of the effects of binding to anionic phospholipids reducing the Ca 2ϩ concentration required for maximal activity and, as such, supports the proposition that the membrane-associated enzyme may already be in a "primed" state, possibly as a result of its association with phosphatidylinositol 4,5-bisphosphate or other anionic phospholipids. It should be noted that the membrane preparations used in the study reported here almost certainly excluded any contribution from nuclear membranes, yet it is often stated that the nuclear membrane is the principal site of cPLA 2 activity in stimulated cells. However, this statement is largely based on studies on cells involved in inflammatory responses where the known co-localization of cyclo-oxygenases and lipoxygenases to the nuclear envelope may be expected to be important in the overall inflammatory response. In other cell types, a significant role for cPLA 2 in generating and modulating oscillatory [Ca 2ϩ ] i signals might be expected to demand a very different cellular localization for the enzyme, especially since this role involves generated arachidonic acid itself rather than any of its metabolites. As noted by Gijón et al. (40) , it is clear that the mechanisms involved in the regulation of cPLA 2 including the relative importance of phosphorylation, Ca 2ϩ , and the site of subcellular localization, show considerable variability in different cell types and even between different agonists in the same cell type.
Finally, it should be emphasized that, in the above arguments, we do not question the validity of the widely reported [Ca 2ϩ ] i -dependent activation of the type IV PLA 2 that is known to reflect the Ca 2ϩ -dependent translocation of the enzyme to the membrane. Such an action can be readily demonstrated, for example, by the addition of Ca 2ϩ ionophores to cells (44 -46) and is generally associated with a maximal activation of the enzyme. Rather, we suggest that, at the low concentrations of agonist used in our studies, a more subtle activation of PLA 2 is revealed that may specifically involve a pool of cPLA 2 that is more directly coupled to receptor activation and is already located at or near its substrate in the membrane. The evidence we have obtained further indicates that the activation of such a putative membrane-associated pool of cPLA 2 by low concentrations of muscarinic agonists probably involves an increase in the phosphorylation state of the enzyme. Obviously, this could be achieved by either an increase in a kinase activity or a decrease in a phosphatase activity. However, based on our previous studies (13) , such an increased phosphorylation cannot involve any PLC-dependent process, including the activation of protein kinase C. Whatever its precise nature and the detailed mechanism of its activation, it is clear that the [Ca 2ϩ ] iindependent activation of this cPLA 2 underlies the generation of arachidonic acid following stimulation of muscarinic receptors at low agonist concentrations. Importantly, it is specifically this generation of arachidonic acid that ultimately results in the activation of the noncapacitative calcium entry pathway that plays such a critical role in the regulation of agonistactivated [Ca 2ϩ ] i oscillations.
